Avelumab in addition to best supportive care (BSC) is in clinical development for the maintenance treatments of adults with locally advanced or metastatic urothelial cancer that did not progress on or following completion of first-line chemotherapy. Urothelial cancer occurs on the lining of the bladder and other parts of the urinary system. In advanced urothelial cancer, cancer has grown into deeper layers including connective tissue or muscle. Metastatic urothelial cancer is when the cancer has spread to other parts of the body, such as the liver or bones. Urothelial cancer usually occurs in patients aged 60 years and older, where patients may have other medical conditions or are not fit enough to be given certain treatments.
Avelumab administered by intravenous infusion is designed to stimulate the body’s own immune system to fight cancer cells. If licensed, avelumab in addition to BSC will offer a maintenance treatment option for patients with locally advanced or metastatic urothelial cancer that did not progress during or following completion of first-line chemotherapy.
Selpercatinib is in clinical development for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer and at the metastatic stage the disease has already spread from the lungs to other sites. Around 2% of these patients will have tumours that contain fusion mutations in the RET gene. Cells in these tumour produce altered RET signalling receptors that allow uncontrolled cancer growth. Currently the only treatment options that attempt to inhibit RET fusion-positive tumour activity are nonselective multikinase inhibitors.